Identifying the Right Patients for Retatrutide: A Clinical Framework for Non-Responder Selection

Not every patient who asks about retatrutide is the right candidate for a retatrutide research program. Patient selection is one of the most important clinical and operational decisions in running a successful program — both because it affects clinical outcomes and because it affects retention, adverse event rates, and the overall quality of your research data.

The patients most likely to benefit from retatrutide — and most likely to remain in your program long-term — share a common profile:

Inadequate response to approved GLP therapies. The clearest clinical indication for escalating to retatrutide is documented inadequate response to semaglutide or tirzepatide at therapeutic doses. "Inadequate response" should be defined in your IRB protocol — a common definition is less than 5% weight loss after 12 weeks at the maximum tolerated dose, or less than 10% weight loss after 24 weeks.

Significant obesity with comorbidities. Patients with BMI ≥35 and at least one obesity-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, non-alcoholic fatty liver disease) have the strongest clinical rationale for a more potent intervention. The risk-benefit calculation for an investigational compound is most favorable in patients with significant disease burden.

Motivated and engaged. Patients who have already invested time and money in a GLP program — even one that did not achieve their goals — have demonstrated motivation. They understand the commitment required. They are more likely to complete the titration phase and remain in the program long-term.

Able to provide meaningful informed consent. Patients must be able to understand the investigational nature of the compound, the requirements of the research program, and the known and unknown risks. Patients with significant cognitive impairment, active psychiatric illness, or language barriers that prevent meaningful consent are not appropriate candidates without additional safeguards.

Your IRB protocol will specify exclusion criteria. Common exclusion criteria for a retatrutide research program include:

• Personal or family history of medullary thyroid carcinoma or MEN2 (consistent with the GLP class labeling)
• Active pancreatitis or history of chronic pancreatitis
• Severe renal impairment (eGFR <30)
• Pregnancy or planned pregnancy during the study period
• Active eating disorder
• Recent cardiovascular event (within 3 months)
• Current use of other investigational compounds

A structured screening process serves both clinical and compliance purposes. Clinically, it identifies patients who meet the inclusion criteria and do not have exclusion criteria. From a compliance perspective, it documents that the enrollment decision was based on a systematic evaluation rather than an ad hoc judgment.

A reasonable screening process includes:

1. Review of prior GLP therapy history (compound, dose, duration, response)
2. Current weight, BMI, and waist circumference
3. Relevant laboratory values (HbA1c, renal function, thyroid function)
4. Review of exclusion criteria
5. Assessment of the patient's understanding of the research framework and willingness to comply with monitoring requirements

Document the screening process in the patient's research record. If a patient does not meet the inclusion criteria or meets an exclusion criterion, document the reason for non-enrollment.

Rigorous patient selection is not just good clinical practice — it is good business. Patients who are well-selected for a retatrutide program are more likely to achieve meaningful results, more likely to complete the titration phase, and more likely to remain in the program long-term. They generate better outcomes data, fewer adverse events, and stronger word-of-mouth referrals.

Patients who are poorly selected — who do not have a clear clinical rationale for retatrutide, who are not motivated to comply with monitoring requirements, or who have contraindications that were not identified at screening — are more likely to drop out, more likely to have adverse events, and more likely to generate complaints.

The time invested in rigorous screening pays dividends in program quality, retention, and reputation.